Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis by Stott, Katharine E et al.
 1 
Population pharmacokinetics and cerebrospinal fluid penetration of fluconazole in adults 1 
with cryptococcal meningitis. 2 
 3 
Katharine E Stotta,b §, Justin Beardsleyc §, Ruwanthi Kolamunnage-Donad, Anahi Santoyo 4 
Castelazoa, Freddie Mukasa Kibengoe, Nguyen Thi Hoang Maif, Jeremy Dayc,g, William Hopea* 5 
 6 
a Centre for Antimicrobial Pharmacodynamics, Department of Molecular and Clinical 7 
Pharmacology, Institute of Translational Medicine, University of Liverpool, UK 8 
b Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi 9 
c Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam 10 
d Department of Biostatistics, Institute of Translational Medicine, University of Liverpool, UK 11 
e MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda 12 
f Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam 13 
g Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, 14 
University of Oxford, UK 15 
§ These authors contributed equally to this work. 16 
* Corresponding author: hopew@liverpool.ac.uk 17 
 18 
Keywords: Cryptococcal meningitis, pharmacokinetics, pharmacodynamics, fluconazole, 19 
central nervous system pharmacokinetics 20 
  21 
AAC Accepted Manuscript Posted Online 18 June 2018
Antimicrob. Agents Chemother. doi:10.1128/AAC.00885-18
Copyright © 2018 Stott et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
 o
n
 July 11, 2018 by University of Liverpool Library
http://aac.asm
.org/
D
ow
nloaded from
 
 2 
ABSTRACT  22 
Robust population pharmacokinetic (PK) data for fluconazole are scarce.  The variability of 23 
fluconazole penetration into the CNS is not known.  A fluconazole PK study was conducted 24 
in 43 patients receiving oral fluconazole (usually 800 mg q24h) in combination with 25 
amphotericin B deoxycholate (1 mg/kg q24h) for cryptococcal meningitis (CM).  A 4-26 
compartment PK model was developed and Monte Carlo simulations performed for a range 27 
of fluconazole dosages.  A meta-analysis of trials reporting outcomes of CM patients treated 28 
with fluconazole monotherapy was performed.  Adjusted for bioavailability, the PK 29 
parameter means (standard deviation) were: clearance, 0.72 (0.24) litres/hour; volume of 30 
the central compartment, 18.07 (6.31) litres; volume of central nervous system (CNS) 31 
compartment, 32.07 (17.60) litres; first-order rate constant from central to peripheral 32 
compartment, 12.20 (11.17) hours-1; from peripheral to central compartment, 18.10 (8.25) 33 
hours-1; from central to CNS compartment 35.43 (13.74) hours-1; from CNS to central 34 
compartment 28.63 (10.03) hours-1. Simulations of area under concentration-time curve 35 
resulted in median (interquartile range) values 1143.2 mg.h/litre (988.4 – 1378.0) in plasma 36 
and 982.9 (781.0 – 1185.9) in CSF after a dosage of 1200mg q24h.  The mean simulated ratio 37 
of AUCCSF:AUCplasma was 0.89 (SD 0.44).  The recommended dosage of fluconazole for CM 38 
induction therapy fails to attain the PD target in respect to the wild-type MIC distribution of 39 
C. neoformans.  The meta-analysis suggested modest improvements in both CSF sterility and 40 
mortality outcomes with escalating dosage.  This study provides the pharmacodynamic 41 
rationale for the long-recognised fact that fluconazole monotherapy is an inadequate 42 
induction regimen for CM.   43 
 44 
 45 
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 3 
 INTRODUCTION 46 
 Mortality from cryptococcal meningitis remains unacceptably high.  More than 90% 47 
of the estimated 223,100 annual incident cases of cryptococcal meningitis occur in Sub-48 
Saharan Africa and Asia-Pacific regions (1).  The most effective regimen for induction is 49 
amphotericin B deoxycholate and flucytosine (2, 3).  However, access to these drugs is 50 
limited in many regions where the burden of cryptococcal meningitis is greatest (4, 5).  In 51 
these settings, high-dose fluconazole is used for induction monotherapy, despite consistent 52 
evidence of reduced survival in comparison with other agents and combinations (6-8). 53 
 Fluconazole was discovered by Pfizer Inc. (Sandwich, UK) in 1978 (9).  The objective 54 
was to discover an orally bioavailable agent for the treatment of invasive mycoses with a 55 
lower propensity to develop resistance than flucytosine (9).  Fluconazole inhibits 56 
cytochrome P450-dependent demethylation of lanosterol in the ergosterol biosynthetic 57 
pathway (10).  The ratio of the area under the concentration-time curve (AUC) to the 58 
minimum inhibitory concentration (MIC) is the pharmacodynamic (PD) index that best links 59 
drug exposure of fluconazole with the observed antifungal effect (11, 12). 60 
 Successful antimicrobial therapy within the central nervous system depends on the 61 
achievement of effective drug concentrations within relevant subcompartments that 62 
include the cerebrum, meninges and CSF (13).  Fluconazole has a low molecular weight 63 
(approximately 300g/mol), is weakly protein bound and is not known to be a substrate for 64 
central nervous system (CNS) efflux pumps (14, 15).  Its ability to partition from the 65 
endovascular compartment into the CNS has been established in laboratory animal models 66 
(16, 17) and clinical studies (18, 19).  Brain:plasma penetration ratios up to 1.33 have been 67 
reported in humans (19).  However, there is a surprising paucity of population 68 
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 4 
pharmacokinetic (PK) data for fluconazole in all clinical contexts.  Furthermore, the extent 69 
and variability of penetration into the CNS is not known.   70 
  The primary aim of this study was to quantify the extent and variability of CNS 71 
penetration of fluconazole in adults with cryptococcal meningitis.  We developed a 72 
population PK model that quantified the inter-individual variability in drug exposure in 73 
plasma and cerebrospinal fluid (CSF).  We investigated the impact of a range of clinically 74 
relevant covariates on fluconazole PK.  Monte Carlo simulation was used to assess the 75 
implications of PK variability in terms of achieving fluconazole PD targets.  Finally, we 76 
conducted a meta-analysis of clinical trials of fluconazole monotherapy to estimate the 77 
contribution of dosage to clinical outcome. 78 
  79 
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 5 
RESULTS 80 
Patients 81 
A total of 43 patients (23 from Vietnam and 20 from Uganda) were recruited over an 82 
11-month period between January and November 2016.  Twenty-two patients (52%) were 83 
female.  The overall median (range) age was 33 years (20 – 73 years), weight 48 kg (32 – 68 84 
kg), body mass index 18 kg/m2 (12 – 25 kg/m2), creatinine at enrolment 70 µmol/L (37 – 167 85 
µmol/L) and estimated glomerular filtration rate using the Cockcroft Gault equation 84.8 86 
mL/min/1.73m2 (35.4 – 146.7 mL/min/1.73m2).  The baseline creatinine concentration was 87 
significantly lower in Vietnamese patients than in Ugandan patients (median 56 versus 79 88 
µmol/L; p-value 0.02).  However, this did not manifest as a significant difference in eGFR 89 
due to different age, sex and weight profiles between the two patient populations.  There 90 
were no statistically significant differences between ethnic groups for other demographic 91 
variables.  The demographic data are shown by ethnicity and for the study population as a 92 
whole in Table 1.   93 
 94 
Pharmacokinetic data 95 
 The final dataset included 312 plasma observations and 52 CSF observations from 96 
the Vietnamese cohort.  From the Ugandan cohort, the dataset included 196 plasma 97 
observations and 115 CSF observations.  A single CSF observation from 1 Ugandan patient 98 
was excluded because no fluconazole was detectable in an isolated sample after 13 days of 99 
therapy.  This was inconsistent with results from other patients and could not be verified. 100 
The mean number of plasma samples and CSF samples per patient was 11.8 and 3.9, 101 
respectively.  Figure 1 shows the raw plasma and CSF concentration-time profiles from study 102 
participants.  103 
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 104 
Population pharmacokinetic analysis 105 
 The final mathematical model was a linear model comprised of an absorption 106 
compartment, central compartment, peripheral compartment and CSF compartment.  The 107 
fit of the final model to the clinical data was acceptable.  The mean parameter estimates 108 
better fitted the data than medians, and were used to calculate Bayesian estimates of drug 109 
exposure for each individual patient.  A linear regression of the observed-versus-predicted 110 
fluconazole concentrations in plasma after the Bayesian step was given by: observed 111 
fluconazole concentration = 1.03*predicted fluconazole concentration + 0.27; r2 = 0.80.  For 112 
the observed-versus-predicted fluconazole concentrations in CSF, the linear regression was 113 
given by observed fluconazole concentration = 1.03*predicted fluconazole concentration - 114 
0.07; r2 = 0.81 (Figure 2 and table 3).  The mean weighted population bias for fluconazole 115 
concentrations in plasma and CSF was 0.20 and -0.30, respectively.  The bias-adjusted 116 
population imprecision in plasma and CSF was 2.21 and 1.55, respectively.  The population 117 
PK parameter estimates for the final model are shown in Table 2. 118 
 119 
Covariate investigation 120 
 Multivariate linear regression of each subject’s covariates versus the Bayesian 121 
posterior parameter values revealed a weak relationship between patient weight and 122 
estimated volume of distribution (slope 0.22, 95% confidence interval for the slope -0.06 to 123 
0.51, p-value 0.05).  Incorporation of weight into the PK model was therefore explored.  124 
However, values for log likelihood, Akaike information criterion (AIC) and population bias 125 
and imprecision were comparable between the 2 models.  The simple base model was 126 
 o
n
 July 11, 2018 by University of Liverpool Library
http://aac.asm
.org/
D
ow
nloaded from
 
 7 
therefore used to describe the data and for the subsequent simulations.  The model 127 
comparisons and the fit to data are summarized in Table 3.  128 
 There was no relationship between the Bayesian estimates of clearance and volume, 129 
and ethnicity or sex in the base model.  The mean (95% CI) clearance was 0.74 liters/hour 130 
(0.64 – 0.83) and 0.71 liters / hour (0.59 – 0.82) for Vietnamese and Ugandan patients, 131 
respectively; p= 0.51.  The mean (95% CI) volume was 16.88 liters (14.33 – 19.44) and 19.44 132 
liters (16.88 – 22.0) for Vietnamese and Ugandan patients, respectively; p= 0.16.  In males, 133 
the mean (95% CI) clearance was 0.79 liters /hour (0.67 – 0.90).  In females, clearance was 134 
0.66 liters / hour (0.57 – 0.75); p= 0.09.  In males, the mean (95% CI) volume was 18.07 liters 135 
(15.47 – 20.67).  In females, volume was 18.07 liters / hour (15.41 – 20.73); p= 0.97.   136 
  137 
Fluconazole penetration into the CSF 138 
 There was large variability in the AUCs generated from each patient’s posterior 139 
estimates.  The 38 patients who received 800mg fluconazole q24h had a median (IQR) 140 
AUC144-168 of 945.4 (799.2 – 1139.8) mg.h/L in plasma and 784.2 mg.h/L (615.9 – 879.4) in 141 
CSF.  From these posterior estimates, the mean ratio of AUCCSF:AUCplasma was 0.82 (standard 142 
deviation 0.22).  143 
Monte Carlo simulation was used to estimate the distribution of drug exposure for 144 
dosages of 400mg, 800mg, 1200mg and 2000mg q24h of fluconazole (Figure 3).  PK 145 
variability was marked, both in plasma and CSF.  After administration of a dosage of 1200mg 146 
fluconazole q24h, median (IQR) simulated plasma AUC144-168 was 1143.2 mg.h/L (988.4 – 147 
1378.0) and CSF AUC144-168 was 982.9 mg.h/L (781.0 – 1185.9).  The mean simulated ratio of 148 
AUCCSF:AUCplasma was 0.89 (SD 0.44).  149 
 150 
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Probability of target attainment analysis 151 
 Monte Carlo simulation was used to predict the probability of achieving a total drug 152 
AUC:MIC ratio of ≥ 389.3 in plasma.  This PD target was shown in a murine model of 153 
cryptococcal meningitis to be associated with a stasis endpoint (i.e. no net change in fungal 154 
density at the end of the experiment compared with that at treatment initiation) (11).  Only 155 
61% of simulated patients receiving 1200mg fluconazole q24h achieved this PD target when 156 
the MIC of the infecting strain was 2.0 mg/L.  For MICs ≥ 4.0mg/L, < 1% of simulated 157 
patients administered 1200mg q24h achieved the PD target (Figure 4). 158 
 159 
Meta-analysis of clinical outcome data 160 
 A systematic review identified 163 relevant manuscripts, of which 11 were 161 
duplicates.  After reviewing titles and abstracts, 28 studies were deemed potentially 162 
relevant for inclusion in the meta-analysis.  Detailed examination of these studies resulted 163 
in the ultimate inclusion of 12 papers describing clinical outcomes from cryptococcal 164 
meningitis treated with fluconazole monotherapy.  In total, 28 patients in 1 study received 165 
200mg fluconazole q24h (20), 19 patients in 2 studies received 400mg fluconazole q24h (7, 166 
21), 97 patients in 3 studies 800mg q24h (22-24), 113 patients in 4 studies 1200mg q24h (8, 167 
23-25), and 1 study described outcomes of 16 patients on 1600mg (24) and 8 patients on 2g 168 
fluconazole q24h (24).  All included patients were HIV positive.  Baseline characteristics and 169 
reported clinical outcomes are presented in Table 4. 170 
The final model suggests that the combination of dose and baseline fungal burden 171 
explains the total heterogeneity in the estimated proportion of patients with sterile CSF 172 
after 10 weeks of treatment (P-value for residual heterogeneity 0.64).  However, there was 173 
not a significant relationship between dose and CSF sterility at 8-10 weeks (p-value 0.45).  174 
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 9 
After adjustment for dose, the test for residual heterogeneity in both 2 and 10-week 175 
mortality was not significant (p-value 0.70 and 0.22, respectively), indicating that dose alone 176 
adequately explained total heterogeneity in mortality outcomes at both time points.  For 177 
both 2 and 10-week mortality outcomes, there was a non-significant trend towards reduced 178 
mortality with escalating dosage (Figure 5). 179 
  180 
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DISCUSSION 181 
 Fluconazole is the only drug available for induction therapy for cryptococcal 182 
meningitis in many regions of the world where the incidence of disease is highest.  An 183 
accumulating body of evidence suggests that fluconazole is a suboptimal agent for this 184 
indication (26).  Whilst this has long been recognised, an explanation for the relatively poor 185 
efficacy of fluconazole is absent.  This study presents a uniquely comprehensive clinical 186 
dataset describing the PK of fluconazole.  It provides robust estimates of CNS penetration 187 
and the variability of those estimates.  A high degree of CNS partitioning has been observed 188 
in previous clinical studies with fluconazole (19, 27).  Distribution into the CNS is facilitated 189 
by low molecular weight, low protein binding and moderate lipophilicity (15, 28).  190 
Fluconazole has proven activity against Cryptococcus neoformans. (29, 30).  This study 191 
provides a further understanding as to why, despite these attributes, fluconazole is an 192 
inferior agent for induction monotherapy for cryptococcal meningitis compared with 193 
amphotericin B deoxycholate (6-8). 194 
 In contrast to previous studies of fluconazole PK (31-33), our data do not suggest a 195 
significant relationship between fluconazole clearance and creatinine clearance, nor 196 
between patient weight and volume of distribution.  The reason for this is not immediately 197 
clear but may relate to the relatively narrow range of creatinine clearance in our population, 198 
and the fact that the vast majority of patients in our cohort had low body weight, with the 199 
range of this covariate also being relatively narrow. 200 
The PK model suggests that current regimens of fluconazole are inadequate for 201 
induction therapy for cryptococcal meningitis.  This has routinely been ascribed to the 202 
overly simplistic notion that fluconazole is a fungistatic agent.  Our analyses provide further 203 
insight into the limitations of this drug.  Previous estimates of fluconazole CNS:plasma 204 
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partition ratios have ranged from 0.52 to 1.33 (18, 19, 27, 34).  We have extended these 205 
estimates by rigorously quantifying the marked variability in the CSF PK.  This variability has 206 
consequences at both microbiological and clinical levels.  Suboptimal exposure of 207 
fluconazole promotes the expansion of intrinsically resistant cryptococcal subpopulations 208 
present at the initiation of therapy (35).  In addition, the evolution of C. neoformans during 209 
therapy to become increasingly triazole resistant has been demonstrated in clinical studies 210 
(36, 37).  To be clinically effective, adequate concentrations of drug must be present at the 211 
site of infection for long enough to exert antimicrobial effect on both susceptible and 212 
resistant subpopulations.  The present analysis demonstrates the challenges in achieving 213 
that aim.   214 
At recommended fluconazole dosages of 1200mg q24h, the probability of PD target 215 
attainment (PTA) bisects the MIC distribution of WT C. neoformans isolates.  This is 216 
consistent with the findings of Sudan et al (11).  Approximately half of patients will fail 217 
therapy because they are not able to generate the drug exposure required to prevent 218 
progressive fungal growth.  Since clinical PK-PD targets are not available for fluconazole in 219 
cryptococcal meningitis, we have used a target derived from a murine study (11).  This 220 
assumes that CNS partitioning is the same in mice and humans.  The cerebrum:plasma AUC 221 
ratio in the murine study was 46.9% (11).  It is conceivable that this is in keeping with our 222 
CSF:plasma AUC ratio of 82%, though clearly it would be preferable to have clinical PK-PD 223 
targets defined.  Nevertheless, our PTA analysis is supported by the 53% 10-week mortality 224 
outcomes for patients receiving 1200mg fluconazole q24h, estimated in the meta-analysis.  225 
Importantly, such PTA analyses are based on an AUC/MIC of 389.3, which is more than an 226 
order of magnitude greater than the AUC/MIC ratio required for Candida albicans (12).   227 
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Progressive escalation of the dosage of fluconazole is not likely to be an effective 228 
strategy for improving cryptococcal meningitis induction therapy.  The drug exposure 229 
required to reliably treat isolates with MICs ≥ 4.0mg/L is difficult to achieve and potentially 230 
toxic.  Our meta-analysis suggests that escalating dosages of fluconazole do not increase the 231 
proportion of patients with sterile CSF at 10 weeks.  Dosages of 2000mg q24h do not appear 232 
to significantly improve 10-week mortality outcomes in comparison to 1200mg q24h.  The 233 
ACTG study (https://clinicaltrials.gov/show/NCT00885703) is investigating the use of higher 234 
dosages of fluconazole (1600mg and 2000mg q24h) for the treatment of cryptococcal 235 
meningitis in HIV-infected individuals and results are pending.  The addition of flucytosine to 236 
high-dose fluconazole (≥ 1200mg q24h) for cryptococcal meningitis increases antifungal 237 
activity and improves mortality outcomes (8, 24), suggesting that combination therapy is 238 
required to optimise antifungal activity in fluconazole-containing regimens. 239 
In summary, this study provides part of the pharmacodynamic rationale for the long-240 
recognised fact that fluconazole monotherapy is an ineffective induction regimen for 241 
cryptococcal meningitis.  We have developed a fluconazole population PK model that 242 
suggests that approximately half of patients with cryptococcal meningitis caused by WT 243 
strains of C. neoformans will be undertreated by currently recommended dosages of 244 
fluconazole for induction therapy.  In doing so we have addressed a knowledge gap 245 
regarding the reason for the inferiority of this drug for cryptococcal meningitis.  There is a 246 
pressing need for improved provision of affordable combination treatments and 247 
development of more effective drugs. 248 
 249 
  250 
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MATERIALS AND METHODS 251 
Clinical pharmacokinetic studies 252 
 Patients from whom plasma and CSF samples were obtained for this PK study have 253 
been described previously (38).  Briefly, adult patients were initially recruited from a multi-254 
centre randomised controlled trial of adjuvant dexamethasone in HIV-associated 255 
cryptococcal meningitis.  The trial is reported elsewhere (n=3, International Standard 256 
Registered Clinical Number 59144167) (39).  Following the early cessation of this trial, 257 
patients were recruited from a prospective descriptive study at the same sites (n=40). Study 258 
sites were The Hospital for Tropical Diseases in Ho Chi Minh City, Vietnam, and Masaka 259 
General Hospital, Uganda. The study protocols were approved by the relevant institutional 260 
review boards and regulatory authorities at each trial site and by the Oxford University 261 
Tropical Research Ethics Committee. 262 
 Fluconazole was administered orally.  Where conscious level did not enable oral 263 
administration, fluconazole was administered via nasogastric tube.  The majority of patients 264 
received 800mg fluconazole q24h.  Two patients received one-off doses of 400mg q24h.  265 
Two received one-off doses of 600mg q24h.  One patient’s regimen of 800mg fluconazole 266 
q24h was escalated to 1200mg q24h for 6 days from day 8 of treatment.  All patients 267 
received combination therapy with amphotericin B deoxycholate 1mg per kg infused over 5-268 
6 hours. 269 
 270 
Measurement of fluconazole concentrations 271 
Fluconazole concentrations were measured using a validated LC/MS/MS 272 
methodology (1260 Agilent UPLC coupled to an Agilent 6420 Triple Quad mass 273 
spectrometer, Agilent Technologies UK Ltd, Cheshire, UK).  Briefly, fluconazole was 274 
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extracted by protein precipitation; 300 µl of cold methanol containing the internal standard 275 
fluconazole-D4 at 0.625 mg/L (TRC, Canada) was added to 10 µl of sample (plasma or CSF). 276 
The solution was vortex mixed for 5 seconds and filtered through a Sirocco precipitation 277 
plate (Waters Ltd, Cheshire, UK). One hundred fifty µl of supernatant was transferred to a 278 
96-well auto sampler plate, and 3 µL were injected on an Agilent ZORBAX C18 RRHD (2.1 X 279 
50mm, 1.8 µm) (Agilent Technologies UK Ltd, Cheshire, UK).  280 
Chromatographic separation was achieved using a gradient consisting of 70% A:30% 281 
B (0.1% formic acid in water as mobile phase A and 0.1% formic acid in methanol as mobile 282 
phase B).  The organic phase was increased to 100% over 90 seconds, with additional 90 283 
seconds of equilibration.   284 
The mass spectrometer was operated in multiple reaction monitoring scan mode in 285 
positive polarity. The precursor ions were 307.11 m/z and 311.1 m/z for fluconazole and 286 
internal standard, respectively. The product ions for fluconazole were 220.1 m/z and 238.1 287 
m/z; for the internal standard 223.2 m/z and 242.1 m/z. The source parameters were set as 288 
follows: capillary voltage 4000 V, gas temperature 300°C and nebulizer gas 15 lb/in2.  289 
The standard curve for fluconazole encompassed the concentration range 1-120 mg/L and 290 
was constructed using blank matrix. The limit of quantitation was 1 mg/L.  In plasma, the 291 
intra-day coefficient of variation (CV) was <3.4% and the inter-day CV was <6.7%, over the 292 
concentration range 1-90 mg/L.  In CSF, the intra-day CV was <5.2% and the inter-day CV 293 
was <5.3% over the same concentration range. 294 
 295 
Population pharmacokinetic modelling 296 
The concentration-time data for fluconazole in plasma and CSF were analysed using 297 
the non-parametric adaptive grid (NPAG) algorithm of the program Pmetrics (40) version 298 
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1.5.0 for R statistical package 3.1.1.  The initial PK mathematical model fitted to the data 299 
contained four compartments and took the following form: 300 
1. 
𝑑𝑋(1)
𝑑𝑡
=  −𝐾𝑎 ∗ 𝑋(1) 301 
2. 
𝑑𝑋(2)
𝑑𝑡
=  𝐾𝑎 ∗ 𝑋(1) − (𝐾𝑐𝑝 +  𝐾𝑐𝑠  +
𝑆𝐶𝐿
𝑉
) ∗ 𝑋(2) + 𝐾𝑠𝑐 ∗ 𝑋(3) +  𝐾𝑝𝑐 ∗ 𝑋(4)  302 
3. 
𝑑𝑋(3)
𝑑𝑡
= 𝐾𝑐𝑠 ∗ 𝑋(2) −  𝐾𝑠𝑐 ∗ 𝑋(3)  303 
4. 
𝑑𝑋(4)
𝑑𝑡
= 𝐾𝑐𝑝 ∗ 𝑋(2) −  𝐾𝑝𝑐 ∗ 𝑋(4) 304 
5. 𝑌(1) =  𝑋(2)/𝑉 305 
6. 𝑌(2) =  𝑋(3)/𝑉𝑐𝑛𝑠 306 
Where equations (1), (2), (3) and (4) describe the rate of change in amount of drug in 307 
milligrams (mg) in the gut, central, CSF and peripheral compartment, respectively.  Ka is the 308 
absorption rate constant from the gut to the central compartment. X(1), X(2), X(3) and X(4) 309 
are the amount of fluconazole (mg) in the gut, central (c), CSF (s) and peripheral 310 
compartments (p), respectively.  Kcp, Kpc, Kcs and Ksc represent first-order transfer 311 
constants connecting the various compartments.  SCL is the first-order clearance of drug 312 
(L/h) from the central compartment.  V is the volume of the central compartment.  The CSF 313 
compartment (X(3)) has an apparent CSF volume (Vcns), given in litres.  314 
 Model error was attributed separately to process noise (including errors in sampling 315 
times or dosing) and assay variance.  Process noise was modelled using lambda, an additive 316 
error term.  The data were weighted by the inverse of the estimated assay variance.   317 
The data for some patients indicated that they had taken fluconazole at an 318 
undocumented time prior to study enrolment, since there was detectable drug in the first 319 
PK sample.  To accommodate this, non-zero initial conditions of all four compartments were 320 
estimated in the structural model.  A switch was coded whereby the parameterised 321 
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 16 
estimate of each initial condition was multiplied by a binary covariate equal to 1 where 322 
fluconazole was detected in the first PK sample, or 0 where no fluconazole was detected in 323 
the first PK sample.  324 
 325 
Population pharmacokinetic covariate screening 326 
 The impact of patent weight, BMI, sex, ethnicity and baseline eGFR on the PK of 327 
fluconazole were investigated.  Bidirectional stepwise multivariate linear regression was 328 
employed to assess the relationship between each covariate and the Bayesian estimates for 329 
volume of distribution and clearance from the central compartment from the standard 330 
population PK model.  Covariates that were retained with significant multivariate p-values 331 
(≤0.05) in the regression model were explored individually.  The relationship between 332 
retained continuous covariates and Bayesian estimates of PK parameters was explored 333 
using univariate linear regression.  The difference between Bayesian estimates of volume 334 
and clearance according to categorical covariates (sex and ethnicity) was compared using 335 
the Mann-Whitney test.   336 
 337 
Population pharmacokinetic model diagnostics 338 
The fit of the model to the data was assessed by visual inspection of diagnostic 339 
scatterplots displaying observed-versus-predicted values before and after the Bayesian step.  340 
Linear regression was performed and the coefficient of determination, intercept and 341 
regression slope noted for each model.  In addition, the log-likelihood value, Akaike 342 
Information criterion (AIC), mean weighted error (a measure of bias) and bias-adjusted, 343 
mean weighted squared error (a measure of precision) were calculated and compared for 344 
each model. 345 
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 346 
Monte Carlo Simulation and calculation of probability of target attainment 347 
 Monte Carlo simulation (n = 5000) was performed in Pmetrics (40).  The support 348 
points from the final joint density were used.  For the simulations, the initial conditions of all 349 
compartments were defaulted to zero.  Fluconazole was administered at a range of dosages: 350 
400mg q24h, 800mg q24h, 1200mg q24h and 2000mg q24h.  The plasma and CSF AUC for 351 
fluconazole was calculated using trapezoidal approximation after the sixth dose, from 144 to 352 
168 hours after treatment initiation.  353 
Wild type fluconazole MIC data were obtained from a previously published collection 354 
of 5,733 C. neoformans isolates estimated using Clinical and Laboratory Standards Institute 355 
(CLSI) methodology (41).  The modal MIC was 4mg/L (1,629 of 5,733 strains; 28%).  Almost 356 
half of strains had MICs ≥ 4mg/L (2,834 of 5,733 strains; 49%).  The epidemiological cut-off 357 
value for C. neoformans versus fluconazole was 8mg/L.  This collection of strains included 358 
molecular types VNI to VNIV and the pattern of MIC distribution was comparable across all 359 
molecular types (41). The proportion of simulated patients that would achieve a previously 360 
published plasma AUC/MIC target of 389.3 was determined.  This target was defined as the 361 
magnitude of drug exposure required for fungal stasis (defined as prevention of progressive 362 
fungal growth) in a murine study that employed CLSI methodology (11).  To our knowledge, 363 
no CSF PK/PD target has been defined in preclinical or clinical studies of fluconazole for 364 
cryptococcal meningitis.  In the present study, the probability of attaining this plasma PK/PD 365 
target was examined at each simulated fluconazole dose. 366 
 367 
 368 
 369 
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Meta-analysis of clinical outcome data 370 
 The AUC/MIC target used in the probability of target attainment analysis was 371 
derived from murine studies.  To enhance clinical relevance, we sought PD data from 372 
humans.  The PD data from patients in the present PK study are confounded by the co-373 
administration of amphotericin B deoxycholate.  For this reason, a search for clinical trials of 374 
fluconazole monotherapy for cryptococcal meningitis was performed.  The electronic 375 
databases Pubmed and Medline were searched on 31st January 2018 using the terms 376 
“fluconazole” and “cryptococcal meningitis”.  Preclinical studies and case reports were 377 
excluded.  To reduce potential heterogeneity, only studies of HIV-positive participants were 378 
included in the meta-analysis.  Baseline variables were chosen a priori for extraction from 379 
the studies if they had previously been determined to have a significant impact on clinical 380 
outcome.  These were mental status, CSF fungal burden and patient age (6, 42).  Where it 381 
was not reported, baseline CSF fungal burden was extrapolated from CSF cryptococcal 382 
antigen titre according to a correlation published by Jarvis et al (6).  383 
 For consistency with the literature, we collected data on clinical outcomes 384 
commonly presented in cryptococcal meningitis trials: CSF sterility at 8-10 weeks, 2-week 385 
mortality and 10-week mortality.  Mixed-effects meta-analysis adjusted for fluconazole 386 
dosage was performed.  Fungal burden in CSF, CD4 count and proportion of patients with 387 
reduced Glasgow Coma Score (GCS) at baseline were explored to assess the degree to which 388 
these modifiers accounted for inter-study heterogeneity in clinical outcome.   The mixed-389 
effects model took the form: 390 
𝜃𝑖 = 𝛽0 + 𝛽1𝑍𝑖1 + ⋯ + 𝛽1𝑍𝑖𝑗 + 𝑢𝑖 
  391 
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where 𝜃𝑖 is the corresponding (unknown) true effect of the 𝑖th study, 𝑍𝑖𝑗 is the value of the 392 
𝑗th moderator variable for the 𝑖th study and 𝑢𝑖 are study-specific random effects such that 393 
𝑢𝑖~𝑁(0, 𝜏
2). Here, 𝜏2 denotes the amount of residual heterogeneity, estimated using the 394 
DerSimonian-Laird estimator (43).  Additional model parameters were estimated via 395 
weighted least squares with weights relative to the estimated 𝜏2.  The null hypothesis 396 
𝐻0: 𝜏
2 = 0 was tested using Cochran’s Q-test, and model parameters were tested with the 397 
Wald-type test statistic. 398 
  399 
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Table 1: Patient demographics 587 
Demographic or clinical 
characteristic 
Vietnam Uganda Combined p-value† 
Sex a (Male:Female) 13:10 8:12 23:20  
Age (years) b 
Mean 
Median 
Range 
 
38 
33 
20 - 73 
 
33 
33 
24 - 50 
 
35 
33 
20 - 73 
0.75 
Weight (kg) c 
Mean 
Median 
Range 
 
46 
45 
32 - 68 
 
49 
49 
35 - 60 
 
48 
48 
32 – 68 
0.23 
BMI (kg/m2) d 
Mean 
Median 
Range 
 
18 
18 
12 - 25 
 
18 
18 
15 - 22 
 
18 
18 
12 - 25 
0.73 
Creatinine (µmol/L) a 
Mean 
Median 
Range 
 
67 
56 
37 – 167 
 
81 
79 
43 - 145 
 
74 
70 
37 - 167 
0.02 
eGFR (ml/min/1.73m2) e 
Mean 
Median 
Range 
 
88.3 
84.8 
35.4 – 136.1 
 
80.7 
81.4 
49.8 – 146.7 
 
84.7 
84.8 
35.4 – 146.7 
0.10 
a n = 43 588 
b n = 31 589 
c n = 41 590 
d n = 35 591 
e n = 33 592 
† p-value for difference between Vietnam and Uganda by Mann-Whitney test of 593 
significance. 594 
BMI: Body Mass Index; eGFR: estimated Glomerular Filtration Rate, by Cockcroft-Gault 595 
equation.  596 
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Table 2: Population parameter estimates from the final 4-compartment pharmacokinetic 597 
model 598 
Parameter Mean Median Standard deviation 
Ka (h-1) 8.78 1.73 11.98 
SCL/F (L/h) 0.72 0.65 0.24 
Volumec /F(L) 18.07 17.41 6.31 
Kcp (h-1) 12.20 8.36 11.17 
Kpc (h-1) 18.10 18.34 8.25 
ICgut (mg) 34.67 49.99 22.74 
ICcentral (mg) 35.86 49.98 19.67 
ICCNS (mg) 31.06 49.96 23.47 
ICperipheral (mg) 34.29 49.96 13.21 
Kcs (h-1) 35.43 42.55 13.74 
Ksc (h-1) 28.63 29.04 10.03 
Volumecns /F(L) 32.07 30.49 17.60 
 599 
SCL: clearance; Volumec: volume of distribution in central compartment; F: bioavailability; 600 
Kcp: first-order rate constant from the central to peripheral compartment; Kpc, first-order 601 
rate constant from peripheral to central compartment; IC: initial conditions in respective 602 
compartments; Kcs: first-order rate constant from the central to CNS compartment; Ksc, 603 
first-order rate constant from CNS to central compartment; Volumecns: volume of 604 
distribution in CNS compartment. 605 
  606 
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Table 3:  Evaluation of the predictive performance of the considered and final models       607 
Model Measured 
compartment 
Log likelihood AIC Population 
bias 
Population 
imprecision 
Linear regression of observed-predicted values 
for each patient 
 
p-value†  
R2, a Intercept Slope 
Model 1 Plasma -2451 4928 0.20 2.21 0.80 0.27 1.03 
0.56 
 CSF -0.30 1.55 0.81 -0.07 1.03 
Model 2 Plasma -2413 4854 0.36 2.38 0.80 0.01 1.03 
 CSF -0.41 1.81 0.80 0.89 1.01 
 608 
Model 1 did not include any covariates.  Model 2 incorporated a function to scale the volume of distribution in central compartment to patient 609 
weight. 610 
AIC: Akaike Information criterion. 611 
a Relative to the regression line fitted for the observed versus predicted values after the Bayesian step. 612 
† Comparison of the joint distribution of population parameter values for each model. 613 
  614 
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Table 4:  Baseline characteristics and clinical outcomes from trial data of fluconazole monotherapy, by dosing regimen 615 
Fluconazole 
dosage (mg) 
Country 
Number 
of 
patients 
Age* 
GCS < 15, 
% 
CD4 cell 
count per 
mm3 * 
CSF 
burden, 
log10 
CFU/mL 
CSF 
sterility, 
fraction 
(%) of 
patients 
Time CSF 
sterility 
charted 
2 week 
mortality 
(%) 
10 week 
mortality (%) 
Reference 
200 Uganda 28 
33 (range 23-
50) 
43 Mean 73 . 4/8 (50) 2 months 10/25 (40) 16/25 (64) 
Mayanja-Kizza 
1998 (20) 
400 USA 14 mean 38(SE 2) 0 
Mean 44 (SE 
13) 
4§ 6/14 (43) 10 weeks NR 4/14 (29) Larsen 1990 (21) 
400 
South 
Africa 
5 39 (37-51) 60 41 5.53 NR NR NR 3/4 (75) Bicanic 2007 (7) 
800 Malawi 58 32 (29-39) 24 37 (11-58) . NR NR 17/58 (29) 33/58 (57) Rothe 2013 (22) 
800 Uganda 30 35 (30-38) 33 7 (3-17) 5.7 NR NR 11/30 (37) 18/30 (60) Longley 2008 (23) 
800 USA 9 35 100 8 4.8§ 1/9 (11) 10 weeks NR 8/9 (89) 
Milefchik 2008 
(24) 
1200 Malawi 47 35 (32-40) 24 36 (17-62) . NR NR 16/47 (34) 26/47 (55) Gaskell 2014 (24) 
1200 Uganda 30 33 (28-42) 60 14 (4-33) 5.9 NR NR 6/27 (22) 13/27 (48) Longley 2008 (23) 
1200 USA 16 40 100 36 3.5§ 6/16 (37.5) 10 weeks NR 10/16 (62.5) 
Milefchik 2008 
(24) 
1200 Malawi 20 
36.5 (range 
27-71) 
40 
25 (range 1-
66) 
5.30 1/20 (5) 2 weeks 7/19 (37) 11/19 (58) 
Nussbaum 2010 
(8) 
1600 USA 16 35 100 33 3§ 
10/16 
(62.5) 
10 weeks NR 6/16 (37.5) 
Milefchik 2008 
(24) 
2000 USA 8 36 100 35 2.4§ 5/8 (62.5) 10 weeks NR 3/8 (37.5) 
Milefchik 2008 
(24) 
 616 
*Median (interquartile rage) unless otherwise specified.  §: Extrapolated from cryptococcal antigen titre.  CSF: Cerebrospinal fluid.  SE: 617 
Standard error.  CFU: Colony-forming units. 618 
 o
n
 July 11, 2018 by University of Liverpool Library
http://aac.asm
.org/
D
ow
nloaded from
 
 29 
Figure 1: Fluconazole concentrations in 43 patients 619 
 620 
Black diamonds represent plasma concentrations.  White triangles represent CSF 621 
concentrations.  622 
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Figure 2:  Scatter plots showing observed versus predicted values for the chosen population 623 
pharmacokinetic model after the Bayesian step. 624 
 625 
 626 
 627 
A: Population predicted concentration of fluconazole in plasma.  R2 = 0.49; intercept = 2.89 (95% CI 0.51 628 
– 5.27), slope = 0.89 (95% CI 0.82 – 0.97) 629 
B:  Individual posterior predicted concentration of fluconazole in plasma.  R2 = 0.80; intercept = 0.27 630 
(95% CI -1.08 – 1.62); slope = 1.03 (95% CI 0.98 – 1.07) 631 
C: Population predicted concentration of fluconazole in CSF.  R2 = 0.46; intercept = 3.39 (95% CI -0.09– 632 
6.87), slope = 1.03 (95% CI 0.87 – 1.2) 633 
D:  Individual posterior predicted concentration of fluconazole in CSF.  R2 = 0.81; intercept = -0.07 (95% CI 634 
-1.97 – 1.84); slope = 1.03 (95% CI 0.95 – 1.10) 635 
 636 
Circles, dashed lines, and solid lines represent individual observed-predicted data points, line of 637 
identity, and the linear regression of observed-predicted values, respectively. All observed and 638 
predicted fluconazole concentrations in mg/L. FLC: fluconazole; CI: Confidence Interval. 639 
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Figure 3:  AUC distributions in 5,000 simulated patients at escalating fluconazole dosages 641 
 642 
Light grey bars indicate simulated plasma AUC144-168.  Dark grey bars indicate simulated CSF 643 
AUC144-168.  644 
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Figure 4: Probability of pharmacodynamic target attainment in plasma as a function of 645 
isolate MIC and fluconazole dosage. 646 
 647 
 648 
 649 
Each line represents the proportion of 5000 simulated patients that achieve the PD target at 650 
the respective dosage of fluconazole.  The PD target was a plasma AUC/MIC ratio ≥ 389.3.  651 
Bars show the proportion of WT strains of C.neoformans at the indicated MIC.  652 
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Figure 5: Meta-analysis of clinical trials of fluconazole monotherapy showing dose-adjusted 654 
effects on A) 2-week mortality and B) 10-week mortality. 655 
 656 
A) 657 
  658 
Right hand column provides observed and estimated proportions of patients dead at 2 659 
weeks. 660 
 661 
 662 
  663 
 o
n
 July 11, 2018 by University of Liverpool Library
http://aac.asm
.org/
D
ow
nloaded from
 
 34 
B) 664 
 665 
Right hand column provides observed and estimated proportions of patients dead at 10 666 
weeks. 667 
 668 
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